190 related articles for article (PubMed ID: 10741734)
21. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review).
Kos J; Lah TT
Oncol Rep; 1998; 5(6):1349-61. PubMed ID: 9769367
[TBL] [Abstract][Full Text] [Related]
22. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors.
Kawasaki G; Kato Y; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284
[TBL] [Abstract][Full Text] [Related]
23. Human cysteine proteinases and their protein inhibitors stefins, cystatins and kininogens.
Turk V; Brzin J; Kotnik M; Lenarcic B; Popović T; Ritonja A; Trstenjak M; Begić-Odobasić L; Machleidt W
Biomed Biochim Acta; 1986; 45(11-12):1375-84. PubMed ID: 3495261
[TBL] [Abstract][Full Text] [Related]
24. Cysteine cathepsins B and L and their inhibitors stefins A and B in carcinoma of the oropharynx: immunohistochemical study.
Strojan P; Oblak I; Gale N; Smid L; Kos J
Histopathology; 2008 Nov; 53(5):612-4. PubMed ID: 18983473
[No Abstract] [Full Text] [Related]
25. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity.
Keyszer G; Lambiri I; Keysser M; Keysser C; Nagel R; Burmester GR; Jung K
Z Rheumatol; 1998 Dec; 57(6):392-8. PubMed ID: 10025098
[TBL] [Abstract][Full Text] [Related]
26. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance.
Russo A; Bazan V; Gebbia N; Pizzolanti G; Tumminello FM; Dardanoni G; Ingria F; Restivo S; Tomasino RM; Leto G
Cancer; 1995 Nov; 76(10):1757-64. PubMed ID: 8625044
[TBL] [Abstract][Full Text] [Related]
27. Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera.
Cimerman N; Brguljan PM; Krasovec M; Suskovic S; Kos J
Clin Chim Acta; 1999 Apr; 282(1-2):211-8. PubMed ID: 10340450
[No Abstract] [Full Text] [Related]
28. Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer.
Krepela E; Procházka J; Kárová B; Cermák J; Roubková H
Neoplasma; 1998; 45(5):318-31. PubMed ID: 9921922
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
[TBL] [Abstract][Full Text] [Related]
30. Cysteine proteinases in cancer progression and their clinical relevance for prognosis.
Lah TT; Kos J
Biol Chem; 1998 Feb; 379(2):125-30. PubMed ID: 9524063
[TBL] [Abstract][Full Text] [Related]
31. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
[TBL] [Abstract][Full Text] [Related]
32. Expression of stefin A is of prognostic significance in squamous cell carcinoma of the head and neck.
Aničin A; Gale N; Smid L; Kos J; Strojan P
Eur Arch Otorhinolaryngol; 2013 Nov; 270(12):3143-51. PubMed ID: 23545885
[TBL] [Abstract][Full Text] [Related]
33. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
Trinkaus M; Vranic A; Dolenc VV; Lah TT
Int J Biol Markers; 2005; 20(1):50-9. PubMed ID: 15832773
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical localization of cathepsin L and cystatin A in normal skin and skin tumors.
Palungwachira P; Kakuta M; Yamazaki M; Yaguchi H; Tsuboi R; Takamori K; Ogawa H
J Dermatol; 2002 Sep; 29(9):573-9. PubMed ID: 12392065
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
Niedergethmann M; Wostbrock B; Sturm JW; Willeke F; Post S; Hildenbrand R
Pancreas; 2004 Oct; 29(3):204-11. PubMed ID: 15367886
[TBL] [Abstract][Full Text] [Related]
36. Cathepsins D, B, and L in malignant human lung tissue.
Ledakis P; Tester WT; Rosenberg N; Romero-Fischmann D; Daskal I; Lah TT
Clin Cancer Res; 1996 Mar; 2(3):561-8. PubMed ID: 9816204
[TBL] [Abstract][Full Text] [Related]
37. Expression and prognostic significance of Cathepsin L in early cutaneous malignant melanoma.
Stabuc B; Mrevlje Z; Markovic J; Stabuc-Silih M
Neoplasma; 2006; 53(3):259-62. PubMed ID: 16652198
[TBL] [Abstract][Full Text] [Related]
38. Elevated expression of T-lymphoma invasion and metastasis inducing factor 1 in squamous-cell carcinoma of the head and neck and its clinical significance.
Wang S; Li S; Yang X; Yang S; Liu S; Liu B; Liu J
Eur J Cancer; 2014 Jan; 50(2):379-87. PubMed ID: 24189000
[TBL] [Abstract][Full Text] [Related]
39. A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells.
Boike G; Lah T; Sloane BF; Rozhin J; Honn K; Guirguis R; Stracke ML; Liotta LA; Schiffmann E
Melanoma Res; 1992; 1(5-6):333-40. PubMed ID: 1422189
[TBL] [Abstract][Full Text] [Related]
40. Cathepsins D, B and L in breast carcinoma and in transformed human breast epithelial cells (HBEC).
Lah TT; Calaf G; Kalman E; Shinde BG; Russo J; Jarosz D; Zabrecky J; Somers R; Daskal I
Biol Chem Hoppe Seyler; 1995 Jun; 376(6):357-63. PubMed ID: 7576229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
